FIG 2.

Expression of V-EM2e/SPΔC1, V-EM2e/SPΔC2, or V-EM2e/ERBD in infected Vero E6 cells. (A) The infection of V-EM2/SPΔC1, V-EM2/SPΔC2 or V-EM2/ERBD in Vero E6 cells induced the cytopathic effects after 4 days postinfection. (B) Representative immunofluorescence images of Vero E6 cells infected with V-EM2e/SPΔC1, V-EM2e/SPΔC2, V-EM2e/ERBD, or mock-infected, stained with anti-SARS-CoV-2 RBD antibody (a to d) or anti-M2e antibody (i to l), and DAPI (e to h, m to p). (C) Vero E6 cells infected with the rescued V-EM2/SPΔC1, V-EM2/SPΔC, or V-EM2/ERBD were lysed and processed with SDS-PAGE followed by WB with a rabbit anti-SARS-CoV-2 RBD antibody (top panel), a mouse antibody against influenza M2e (top second gel), anti-VSV nucleocapsid (N) (top third gel), or anti-action (a cellular protein as an internal control) (low panel).